The award was presented on February 20 in Warsaw during the Polish Science Gala, an annual event celebrating Polish Science Day. During the ceremony, Minister Marcin Kulasek honored Poland’s most eminent researchers across five categories: lifetime achievement, as well as scientific, teaching, organizational, and implementation activities.

Addressing the laureates, the Minister highlighted the broader social and civilizational impact of their work:

“We all deeply respect your readiness to share knowledge, experience, and passion. It is precisely this attitude that makes science a living, continuous process—passed on, developed, and creatively deepened by successive generations.”

The laureate of the award for implementation activities, Prof. Krzysztof Kamiński, works at the Department of Drug Chemistry (Chair of Pharmaceutical Chemistry, UJ CM). His research focuses on the discovery of new active substances that could be used in the treatment of severe neurological conditions, including Parkinson’s disease.

The crowning implementation success of his team is the development of the iQ-007 molecule, designed for the treatment of drug-resistant epilepsy and neurodegenerative diseases. The process of bringing this medical innovation to life is gaining impressive momentum. In January 2025, the U.S. Food and Drug Administration (FDA) granted the iQ-007 molecule Orphan Drug Designation for the treatment of Dravet syndrome, an exceptionally rare genetic disorder that appears in early childhood. Just two months later, the Human Research Ethics Committee (HREC) in Australia approved the initiation of Phase I clinical trials involving healthy volunteers.

1771677790827

1771677790870

1771677790802

1771677791187

1771677790975